AST 0 3 0 3 B-clinical_variable
( 4 5 4 5 I-clinical_variable
SGOT)/ALT 5 14 5 14 I-clinical_variable
( 15 16 15 16 I-clinical_variable
SGPT 16 20 16 20 I-clinical_variable
): 20 22 20 22 I-clinical_variable
= 23 24 23 24 O
< 24 25 24 25 O
3 26 27 26 27 B-upper_bound
x 28 29 28 29 I-upper_bound
ULN 30 33 30 33 I-upper_bound
( 34 35 34 35 O
within 35 41 35 41 O
2 42 43 42 43 B-upper_bound
weeks 44 49 44 49 I-upper_bound
prior 50 55 50 55 I-upper_bound
to 56 58 56 58 O
enrollment 59 69 59 69 O
) 69 70 69 70 O
( 71 72 71 72 O
participants 72 84 72 84 O
may 85 88 85 88 O
receive 89 96 89 96 O
GCSF 97 101 97 101 O
and 102 105 102 105 O
transfusions 106 118 106 118 O
to 119 121 119 121 O
meet 122 126 122 126 O
these 127 132 127 132 O
parameters 133 143 133 143 O
) 143 144 143 144 O

AST 0 3 145 148 B-clinical_variable
( 4 5 149 150 I-clinical_variable
serum 5 10 150 155 I-clinical_variable
glutamic 11 19 156 164 I-clinical_variable
oxaloacetic 20 31 165 176 I-clinical_variable
transaminase 32 44 177 189 I-clinical_variable
[ 45 46 190 191 I-clinical_variable
SGOT])/ALT 46 56 191 201 I-clinical_variable
( 57 58 202 203 I-clinical_variable
serum 58 63 203 208 I-clinical_variable
glutamate 64 73 209 218 I-clinical_variable
pyruvate 74 82 219 227 I-clinical_variable
transaminase 83 95 228 240 I-clinical_variable
[ 96 97 241 242 I-clinical_variable
SGPT 97 101 242 246 I-clinical_variable
] 101 102 246 247 I-clinical_variable
) 102 103 247 248 O
= 104 105 249 250 O
< 105 106 250 251 O
3 107 108 252 253 B-upper_bound
x 109 110 254 255 I-upper_bound
ULN 111 114 256 259 I-upper_bound
( 115 116 260 261 O
within 116 122 261 267 O
2 123 124 268 269 B-upper_bound
weeks 125 130 270 275 I-upper_bound
prior 131 136 276 281 I-upper_bound
to 137 139 282 284 O
enrollment 140 150 285 295 O
) 150 151 295 296 O

Absolute 0 8 297 305 B-clinical_variable
neutrophil 9 19 306 316 I-clinical_variable
count 20 25 317 322 I-clinical_variable
> 26 27 323 324 O
= 27 28 324 325 O
1,000 29 34 326 331 B-lower_bound
/ 34 35 331 332 I-lower_bound
mm^3 35 39 332 336 I-lower_bound
( 40 41 337 338 O
within 41 47 338 344 O
2 48 49 345 346 B-upper_bound
weeks 50 55 347 352 I-upper_bound
prior 56 61 353 358 I-upper_bound
to 62 64 359 361 O
enrollment 65 75 362 372 O
) 75 76 372 373 O

CD4 0 3 374 377 B-clinical_variable
cell 4 8 378 382 I-clinical_variable
count 9 14 383 388 I-clinical_variable
of 15 17 389 391 O
at 18 20 392 394 O
least 21 26 395 400 O
100 27 30 401 404 B-upper_bound
cells 31 36 405 410 I-upper_bound
/ 36 37 410 411 I-upper_bound
mm^3 37 41 411 415 I-upper_bound

Creatinine 0 10 416 426 B-clinical_variable
< 11 12 427 428 O
1.5 13 16 429 432 B-upper_bound
UNL 17 20 433 436 I-upper_bound
or 21 23 437 439 O
creatinine 24 34 440 450 B-clinical_variable
clearance 35 44 451 460 I-clinical_variable
( 45 46 461 462 I-clinical_variable
CrCl 46 50 462 466 I-clinical_variable
) 50 51 466 467 I-clinical_variable
> 52 53 468 469 O
50 54 56 470 472 B-lower_bound
ml 57 59 473 475 I-lower_bound
/ 59 60 475 476 I-lower_bound
min 60 63 476 479 I-lower_bound
( 64 65 480 481 O
within 65 71 481 487 O
2 72 73 488 489 B-upper_bound
weeks 74 79 490 495 I-upper_bound
prior 80 85 496 501 I-upper_bound
to 86 88 502 504 O
enrollment 89 99 505 515 O
) 99 100 515 516 O

Creatinine 0 10 517 527 B-clinical_variable
: 10 11 527 528 O
< 12 13 529 530 O
1.5 14 17 531 534 B-upper_bound
x 18 19 535 536 I-upper_bound
upper 20 25 537 542 I-upper_bound
normal 26 32 543 549 I-upper_bound
limit 33 38 550 555 I-upper_bound
( 39 40 556 557 I-upper_bound
UNL 40 43 557 560 I-upper_bound
) 43 44 560 561 I-upper_bound
or 45 47 562 564 O
CrCl 48 52 565 569 B-clinical_variable
> 53 54 570 571 O
50ml 55 59 572 576 B-lower_bound
/ 59 60 576 577 I-lower_bound
min 60 63 577 580 I-lower_bound
( 64 65 581 582 O
within 65 71 582 588 O
2 72 73 589 590 B-upper_bound
weeks 74 79 591 596 I-upper_bound
prior 80 85 597 602 I-upper_bound
to 86 88 603 605 O
enrollment 89 99 606 616 O
) 99 100 616 617 O
( 101 102 618 619 O
participants 102 114 619 631 O
may 115 118 632 635 O
receive 119 126 636 643 O
GCSF 127 131 644 648 O
and 132 135 649 652 O
transfusions 136 148 653 665 O
to 149 151 666 668 O
meet 152 156 669 673 O
these 157 162 674 679 O
parameters 163 173 680 690 O
) 173 174 690 691 O

Eastern 0 7 692 699 B-clinical_variable
Cooperative 8 19 700 711 I-clinical_variable
Oncology 20 28 712 720 I-clinical_variable
Group 29 34 721 726 I-clinical_variable
( 35 36 727 728 I-clinical_variable
ECOG 36 40 728 732 I-clinical_variable
) 40 41 732 733 I-clinical_variable
performance 42 53 734 745 I-clinical_variable
status 54 60 746 752 I-clinical_variable
= 61 62 753 754 O
< 62 63 754 755 O
1 64 65 756 757 B-upper_bound
( 66 67 758 759 O
Karnofsky 67 76 759 768 B-clinical_variable
> 77 78 769 770 O
= 78 79 770 771 O
70 80 82 772 774 B-lower_bound
% 82 83 774 775 I-lower_bound
) 83 84 775 776 O

For 0 3 777 780 O
Stratum 4 11 781 788 O
1 12 13 789 790 O
: 13 14 790 791 O
CD4 15 18 792 795 B-clinical_variable
+ 18 19 795 796 I-clinical_variable
cell 20 24 797 801 I-clinical_variable
count 25 30 802 807 I-clinical_variable
greater 31 38 808 815 O
than 39 43 816 820 O
200 44 47 821 824 B-lower_bound
cells 48 53 825 830 I-lower_bound
/ 53 54 830 831 I-lower_bound
mm^3 54 58 831 835 I-lower_bound
obtained 59 67 836 844 O
within 68 74 845 851 O
2 75 76 852 853 B-upper_bound
weeks 77 82 854 859 I-upper_bound
prior 83 88 860 865 I-upper_bound
to 89 91 866 868 O
enrollment 92 102 869 879 O
at 103 105 880 882 O
any 106 109 883 886 O
United 110 116 887 893 O
States 117 123 894 900 O
( 124 125 901 902 O
U.S. 125 129 902 906 O
) 129 130 906 907 O
laboratory 131 141 908 918 O
that 142 146 919 923 O
has 147 150 924 927 O
a 151 152 928 929 O
clinical 153 161 930 938 O
laboratory 162 172 939 949 O
improvement 173 184 950 961 O
amendments 185 195 962 972 O
( 196 197 973 974 O
CLIA 197 201 974 978 O
) 201 202 978 979 O
certification 203 216 980 993 O
or 217 219 994 996 O
its 220 223 997 1000 O
equivalent 224 234 1001 1011 O

For 0 3 1012 1015 O
Stratum 4 11 1016 1023 O
2 12 13 1024 1025 O
: 13 14 1025 1026 O
CD4 15 18 1027 1030 B-clinical_variable
cell 19 23 1031 1035 I-clinical_variable
count 24 29 1036 1041 I-clinical_variable
between 30 37 1042 1049 O
100 38 41 1050 1053 B-lower_bound
- 41 42 1053 1054 O
200 42 45 1054 1057 B-upper_bound
cells 46 51 1058 1063 I-upper_bound
/ 51 52 1063 1064 I-upper_bound
mm^3 52 56 1064 1068 I-upper_bound
obtained 57 65 1069 1077 O
within 66 72 1078 1084 O
2 73 74 1085 1086 B-upper_bound
weeks 75 80 1087 1092 I-upper_bound
prior 81 86 1093 1098 I-upper_bound
to 87 89 1099 1101 O
enrollment 90 100 1102 1112 O
at 101 103 1113 1115 O
any 104 107 1116 1119 O
U.S. 108 112 1120 1124 O
laboratory 113 123 1125 1135 O
that 124 128 1136 1140 O
has 129 132 1141 1144 O
a 133 134 1145 1146 O
clinical 135 143 1147 1155 O
laboratory 144 154 1156 1166 O
improvement 155 166 1167 1178 O
amendments 167 177 1179 1189 O
( 178 179 1190 1191 O
CLIA 179 183 1191 1195 O
) 183 184 1195 1196 O
certification 185 198 1197 1210 O
or 199 201 1211 1213 O
its 202 205 1214 1217 O
equivalent 206 216 1218 1228 O

For 0 3 1229 1232 O
participants 4 16 1233 1245 O
in 17 19 1246 1248 O
the 20 23 1249 1252 O
24 24 26 1253 1255 O
participant 27 38 1256 1267 O
solid 39 44 1268 1273 B-cancer
tumor 45 50 1274 1279 I-cancer
cohort 51 57 1280 1286 O
, 57 58 1286 1287 O
only 59 63 1288 1292 O
those 64 69 1293 1298 O
histologies 70 81 1299 1310 O
not 82 85 1311 1314 O
known 86 91 1315 1320 O
to 92 94 1321 1323 O
respond 95 102 1324 1331 O
to 103 105 1332 1334 O
single 106 112 1335 1341 O
agent 113 118 1342 1347 O
nivolumab 119 128 1348 1357 B-treatment
( 129 130 1358 1359 O
such 130 134 1359 1363 O
as 135 137 1364 1366 O
pancreas 138 146 1367 1375 B-cancer
, 146 147 1375 1376 O
prostate 148 156 1377 1385 B-cancer
, 156 157 1385 1386 O
and 158 161 1387 1390 O
microsatellite 162 176 1391 1405 B-cancer
stable 177 183 1406 1412 I-cancer
[ 184 185 1413 1414 I-cancer
MSS 185 188 1414 1417 I-cancer
] 188 189 1417 1418 I-cancer
colorectal 190 200 1419 1429 I-cancer
cancer 201 207 1430 1436 I-cancer
) 207 208 1436 1437 O

HIV 0 3 1438 1441 B-chronic_disease
viral 4 9 1442 1447 O
load 10 14 1448 1452 O
should 15 21 1453 1459 O
be 22 24 1460 1462 O
well 25 29 1463 1467 O
suppressed 30 40 1468 1478 O
, 40 41 1478 1479 O
defined 42 49 1480 1487 O
as 50 52 1488 1490 O
below 53 58 1491 1496 O
the 59 62 1497 1500 O
limit 63 68 1501 1506 O
of 69 71 1507 1509 O
detection 72 81 1510 1519 O
of 82 84 1520 1522 O
the 85 88 1523 1526 O
local 89 94 1527 1532 O
assay 95 100 1533 1538 O
or 101 103 1539 1541 O
below 104 109 1542 1547 O
75 110 112 1548 1550 B-upper_bound
copies 113 119 1551 1557 I-upper_bound
/ 119 120 1557 1558 I-upper_bound
mL 120 122 1558 1560 I-upper_bound
by 123 125 1561 1563 O
Food 126 130 1564 1568 O
and 131 134 1569 1572 O
Drug 135 139 1573 1577 O
Administration 140 154 1578 1592 O
( 155 156 1593 1594 O
FDA)-approved 156 169 1594 1607 O
assays 170 176 1608 1614 O
, 176 177 1614 1615 O
within 178 184 1616 1622 O
4 185 186 1623 1624 B-upper_bound
weeks 187 192 1625 1630 I-upper_bound
prior 193 198 1631 1636 I-upper_bound
to 199 201 1637 1639 O
registration 202 214 1640 1652 O

HIV-1 0 5 1653 1658 B-chronic_disease
infection 6 15 1659 1668 I-chronic_disease
, 15 16 1668 1669 O
as 17 19 1670 1672 O
documented 20 30 1673 1683 O
by 31 33 1684 1686 O
any 34 37 1687 1690 O
federally 38 47 1691 1700 O
approved 48 56 1701 1709 O
, 56 57 1709 1710 O
licensed 58 66 1711 1719 O
HIV 67 70 1720 1723 B-treatment
rapid 71 76 1724 1729 I-treatment
test 77 81 1730 1734 I-treatment
performed 82 91 1735 1744 O
in 92 94 1745 1747 O
conjunction 95 106 1748 1759 O
with 107 111 1760 1764 O
screening 112 121 1765 1774 O
( 122 123 1775 1776 O
or 123 125 1776 1778 O
enzyme 126 132 1779 1785 B-treatment
linked 133 139 1786 1792 I-treatment
immunosorbent 140 153 1793 1806 I-treatment
assay 154 159 1807 1812 I-treatment
[ 160 161 1813 1814 I-treatment
ELISA 161 166 1814 1819 I-treatment
] 166 167 1819 1820 I-treatment
, 167 168 1820 1821 O
test 169 173 1822 1826 O
kit 174 177 1827 1830 O
, 177 178 1830 1831 O
and 179 182 1832 1835 O
confirmed 183 192 1836 1845 O
by 193 195 1846 1848 O
Western 196 203 1849 1856 O
blot 204 208 1857 1861 O
or 209 211 1862 1864 O
other 212 217 1865 1870 O
approved 218 226 1871 1879 O
test 227 231 1880 1884 O
) 231 232 1884 1885 O
; 232 233 1885 1886 O
alternatively 234 247 1887 1900 O
, 247 248 1900 1901 O
this 249 253 1902 1906 O
documentation 254 267 1907 1920 O
may 268 271 1921 1924 O
include 272 279 1925 1932 O
a 280 281 1933 1934 O
record 282 288 1935 1941 O
demonstrating 289 302 1942 1955 O
that 303 307 1956 1960 O
another 308 315 1961 1968 O
physician 316 325 1969 1978 O
has 326 329 1979 1982 O
documented 330 340 1983 1993 O
the 341 344 1994 1997 O
participant 345 356 1998 2009 O
's 356 358 2009 2011 O
HIV 359 362 2012 2015 O
status 363 369 2016 2022 O

Hemoglobin 0 10 2023 2033 B-clinical_variable
> 11 12 2034 2035 O
= 12 13 2035 2036 O
9 14 15 2037 2038 B-lower_bound
g 16 17 2039 2040 I-lower_bound
/ 17 18 2040 2041 I-lower_bound
dL 18 20 2041 2043 I-lower_bound
( 21 22 2044 2045 O
within 22 28 2045 2051 O
2 29 30 2052 2053 B-upper_bound
weeks 31 36 2054 2059 I-upper_bound
prior 37 42 2060 2065 I-upper_bound
to 43 45 2066 2068 O
enrollment 46 56 2069 2079 O
) 56 57 2079 2080 O

History 0 7 2081 2088 O
of 8 10 2089 2091 O
allergic 11 19 2092 2100 O
reactions 20 29 2101 2110 O
attributed 30 40 2111 2121 O
to 41 43 2122 2124 O
compounds 44 53 2125 2134 O
of 54 56 2135 2137 O
similar 57 64 2138 2145 O
chemical 65 73 2146 2154 O
or 74 76 2155 2157 O
biologic 77 85 2158 2166 O
composition 86 97 2167 2178 O
to 98 100 2179 2181 O
ipilimumab 101 111 2182 2192 B-allergy_name
, 111 112 2192 2193 O
nivolumab 113 122 2194 2203 B-allergy_name
, 122 123 2203 2204 O
or 124 126 2205 2207 O
other 127 132 2208 2213 O
agents 133 139 2214 2220 O
used 140 144 2221 2225 O
in 145 147 2226 2228 O
study 148 153 2229 2234 O
, 153 154 2234 2235 O
or 155 157 2236 2238 O
history 158 165 2239 2246 O
of 166 168 2247 2249 O
severe 169 175 2250 2256 O
hypersensitivity 176 192 2257 2273 O
reaction 193 201 2274 2282 O
to 202 204 2283 2285 O
any 205 208 2286 2289 O
monoclonal 209 219 2290 2300 B-allergy_name
antibody 220 228 2301 2309 I-allergy_name

Leukocyte 0 9 2310 2319 B-clinical_variable
count 10 15 2320 2325 I-clinical_variable
: 15 16 2325 2326 O
no 17 19 2327 2329 O
lower 20 25 2330 2335 O
limit 26 31 2336 2341 O
( 32 33 2342 2343 O
within 33 39 2343 2349 O
2 40 41 2350 2351 B-upper_bound
weeks 42 47 2352 2357 I-upper_bound
prior 48 53 2358 2363 I-upper_bound
to 54 56 2364 2366 O
enrollment 57 67 2367 2377 O
) 67 68 2377 2378 O
( 69 70 2379 2380 O
participants 70 82 2380 2392 O
may 83 86 2393 2396 O
receive 87 94 2397 2404 O
granulocyte 95 106 2405 2416 O
colony 107 113 2417 2423 I-clinical_variable
stimulating 114 125 2424 2435 I-clinical_variable
factor 126 132 2436 2442 I-clinical_variable
[ 133 134 2443 2444 I-clinical_variable
GCSF 134 138 2444 2448 I-clinical_variable
] 138 139 2448 2449 I-clinical_variable
and 140 143 2450 2453 O
transfusions 144 156 2454 2466 O
to 157 159 2467 2469 O
meet 160 164 2470 2474 O
these 165 170 2475 2480 O
parameters 171 181 2481 2491 O
) 181 182 2491 2492 O

Leukocytes 0 10 2493 2503 B-upper_bound
> 11 12 2504 2505 O
= 12 13 2505 2506 O
2,000 14 19 2507 2512 B-lower_bound
/ 19 20 2512 2513 I-lower_bound
mm^3 20 24 2513 2517 I-lower_bound
( 25 26 2518 2519 O
within 26 32 2519 2525 O
2 33 34 2526 2527 B-upper_bound
weeks 35 40 2528 2533 I-upper_bound
prior 41 46 2534 2539 I-upper_bound
to 47 49 2540 2542 O
enrollment 50 60 2543 2553 O
) 60 61 2553 2554 O

Participants 0 12 2555 2567 O
MUST 13 17 2568 2572 O
receive 18 25 2573 2580 O
appropriate 26 37 2581 2592 O
care 38 42 2593 2597 O
and 43 46 2598 2601 O
treatment 47 56 2602 2611 B-treatment
for 57 60 2612 2615 O
HIV 61 64 2616 2619 B-chronic_disease
infection 65 74 2620 2629 I-chronic_disease
, 74 75 2629 2630 O
including 76 85 2631 2640 O
antiretroviral 86 100 2641 2655 B-treatment
medications 101 112 2656 2667 I-treatment
when 113 117 2668 2672 O
clinically 118 128 2673 2683 O
indicated 129 138 2684 2693 O
, 138 139 2693 2694 O
and 140 143 2695 2698 O
should 144 150 2699 2705 O
be 151 153 2706 2708 O
under 154 159 2709 2714 O
the 160 163 2715 2718 O
care 164 168 2719 2723 O
of 169 171 2724 2726 O
a 172 173 2727 2728 O
physician 174 183 2729 2738 O
experienced 184 195 2739 2750 O
in 196 198 2751 2753 O
HIV 199 202 2754 2757 O
management 203 213 2758 2768 O

Participants 0 12 2769 2781 O
must 13 17 2782 2786 O
have 18 22 2787 2791 O
histologically 23 37 2792 2806 O
confirmed 38 47 2807 2816 O
solid 48 53 2817 2822 B-cancer
tumor 54 59 2823 2828 I-cancer
malignancy 60 70 2829 2839 I-cancer
that 71 75 2840 2844 O
is 76 78 2845 2847 O
metastatic 79 89 2848 2858 B-cancer
or 90 92 2859 2861 O
unresectable 93 105 2862 2874 O
and 106 109 2875 2878 O
for 110 113 2879 2882 O
which 114 119 2883 2888 O
standard 120 128 2889 2897 O
curative 129 137 2898 2906 O
or 138 140 2907 2909 O
palliative 141 151 2910 2920 O
measures 152 160 2921 2929 O
do 161 163 2930 2932 O
not 164 167 2933 2936 O
exist 168 173 2937 2942 O
or 174 176 2943 2945 O
are 177 180 2946 2949 O
no 181 183 2950 2952 O
longer 184 190 2953 2959 O
effective 191 200 2960 2969 O

Participants 0 12 2970 2982 O
must 13 17 2983 2987 O
have 18 22 2988 2992 O
measurable 23 33 2993 3003 O
disease 34 41 3004 3011 O
, 41 42 3011 3012 O
defined 43 50 3013 3020 O
as 51 53 3021 3023 O
at 54 56 3024 3026 O
least 57 62 3027 3032 O
one 63 66 3033 3036 B-lower_bound
lesion 67 73 3037 3043 O
that 74 78 3044 3048 O
can 79 82 3049 3052 O
be 83 85 3053 3055 O
accurately 86 96 3056 3066 O
measured 97 105 3067 3075 O
in 106 108 3076 3078 O
at 109 111 3079 3081 O
least 112 117 3082 3087 O
one 118 121 3088 3091 O
dimension 122 131 3092 3101 B-clinical_variable
( 132 133 3102 3103 O
longest 133 140 3103 3110 O
diameter 141 149 3111 3119 B-clinical_variable
to 150 152 3120 3122 O
be 153 155 3123 3125 O
recorded 156 164 3126 3134 O
for 165 168 3135 3138 O
non 169 172 3139 3142 O
- 172 173 3142 3143 O
nodal 173 178 3143 3148 B-clinical_variable
lesions 179 186 3149 3156 I-clinical_variable
and 187 190 3157 3160 O
short 191 196 3161 3166 O
axis 197 201 3167 3171 O
for 202 205 3172 3175 O
nodal 206 211 3176 3181 O
lesions 212 219 3182 3189 O
) 219 220 3189 3190 O
as 221 223 3191 3193 O
> 224 225 3194 3195 O
= 225 226 3195 3196 O
20 227 229 3197 3199 B-lower_bound
mm 230 232 3200 3202 I-lower_bound
with 233 237 3203 3207 O
conventional 238 250 3208 3220 O
techniques 251 261 3221 3231 O
or 262 264 3232 3234 O
as 265 267 3235 3237 O
> 268 269 3238 3239 O
= 269 270 3239 3240 O
10 271 273 3241 3243 B-lower_bound
mm 274 276 3244 3246 I-lower_bound
with 277 281 3247 3251 O
spiral 282 288 3252 3258 B-treatment
computed 289 297 3259 3267 I-treatment
tomography 298 308 3268 3278 I-treatment
( 309 310 3279 3280 I-treatment
CT 310 312 3280 3282 I-treatment
) 312 313 3282 3283 I-treatment
scan 314 318 3284 3288 I-treatment
, 318 319 3288 3289 O
magnetic 320 328 3290 3298 B-treatment
resonance 329 338 3299 3308 I-treatment
imaging 339 346 3309 3316 I-treatment
( 347 348 3317 3318 I-treatment
MRI 348 351 3318 3321 I-treatment
) 351 352 3321 3322 I-treatment
, 352 353 3322 3323 O
or 354 356 3324 3326 O
calipers 357 365 3327 3335 B-treatment
by 366 368 3336 3338 O
clinical 369 377 3339 3347 O
exam 378 382 3348 3352 O

Participants 0 12 3353 3365 O
who 13 16 3366 3369 O
have 17 21 3370 3374 O
hepatitis 22 31 3375 3384 B-chronic_disease
C 32 33 3385 3386 I-chronic_disease
( 34 35 3387 3388 O
both 35 39 3388 3392 O
reactive 40 48 3393 3401 O
anti 49 53 3402 3406 O
- 53 54 3406 3407 O
hepatitis 54 63 3407 3416 B-chronic_disease
C 64 65 3417 3418 I-chronic_disease
virus 66 71 3419 3424 I-chronic_disease
[ 72 73 3425 3426 I-chronic_disease
HCV 73 76 3426 3429 I-chronic_disease
] 76 77 3429 3430 I-chronic_disease
antibody 78 86 3431 3439 O
and 87 90 3440 3443 O
detectable 91 101 3444 3454 O
HCV 102 105 3455 3458 O
ribonucleic 106 117 3459 3470 O
acid 118 122 3471 3475 O
[ 123 124 3476 3477 O
RNA 124 127 3477 3480 O
] 127 128 3480 3481 O
) 128 129 3481 3482 O
and 130 133 3483 3486 O
hepatitis 134 143 3487 3496 B-chronic_disease
B 144 145 3497 3498 I-chronic_disease
( 146 147 3499 3500 O
hepatitis 147 156 3500 3509 O
B 157 158 3510 3511 O
surface 159 166 3512 3519 O
antigen 167 174 3520 3527 O
[ 175 176 3528 3529 O
HBsAg 176 181 3529 3534 O
] 181 182 3534 3535 O
positive 183 191 3536 3544 O
and 192 195 3545 3548 O
anti 196 200 3549 3553 O
- 200 201 3553 3554 O
hepatitis 201 210 3554 3563 O
B 211 212 3564 3565 O
core 213 217 3566 3570 O
[ 218 219 3571 3572 O
HBc]-total 219 229 3572 3582 O
positive 230 238 3583 3591 O
) 238 239 3591 3592 O
, 239 240 3592 3593 O
may 241 244 3594 3597 O
be 245 247 3598 3600 O
enrolled 248 256 3601 3609 O
, 256 257 3609 3610 O
provided 258 266 3611 3619 O
total 267 272 3620 3625 B-clinical_variable
bilirubin 273 282 3626 3635 I-clinical_variable
is 283 285 3636 3638 O
= 286 287 3639 3640 O
< 287 288 3640 3641 O
1.5 289 292 3642 3645 B-upper_bound
x 293 294 3646 3647 I-upper_bound
institutional 295 308 3648 3661 I-upper_bound
ULN 309 312 3662 3665 I-upper_bound
, 312 313 3665 3666 O
and 314 317 3667 3670 O
AST 318 321 3671 3674 B-clinical_variable
( 322 323 3675 3676 I-clinical_variable
SGOT 323 327 3676 3680 I-clinical_variable
) 327 328 3680 3681 I-clinical_variable
and 329 332 3682 3685 O
ALT 333 336 3686 3689 B-clinical_variable
( 337 338 3690 3691 I-clinical_variable
SGPT 338 342 3691 3695 I-clinical_variable
) 342 343 3695 3696 I-clinical_variable
must 344 348 3697 3701 O
be 349 351 3702 3704 O
= 352 353 3705 3706 O
< 353 354 3706 3707 O
3 355 356 3708 3709 B-upper_bound
X 357 358 3710 3711 I-upper_bound
institutional 359 372 3712 3725 I-upper_bound
upper 373 378 3726 3731 I-upper_bound
limit 379 384 3732 3737 I-upper_bound
of 385 387 3738 3740 I-upper_bound
normal 388 394 3741 3747 I-upper_bound
, 394 395 3747 3748 O
and 396 399 3749 3752 O
hepatitis 400 409 3753 3762 B-clinical_variable
B 410 411 3763 3764 I-clinical_variable
virus 412 417 3765 3770 I-clinical_variable
( 418 419 3771 3772 I-clinical_variable
HBV 419 422 3772 3775 I-clinical_variable
) 422 423 3775 3776 I-clinical_variable
deoxyribonucleic 424 440 3777 3793 I-clinical_variable
acid 441 445 3794 3798 I-clinical_variable
( 446 447 3799 3800 I-clinical_variable
DNA 447 450 3800 3803 I-clinical_variable
) 450 451 3803 3804 I-clinical_variable
< 452 453 3805 3806 O
100 454 457 3807 3810 B-upper_bound
IU 458 460 3811 3813 I-upper_bound
/ 460 461 3813 3814 I-upper_bound
mL 461 463 3814 3816 I-upper_bound
( 464 465 3817 3818 O
if 465 467 3818 3820 O
hepatitis 468 477 3821 3830 O
B 478 479 3831 3832 O
positive 480 488 3833 3841 O
) 488 489 3841 3842 O
within 490 496 3843 3849 O
2 497 498 3850 3851 B-upper_bound
weeks 499 504 3852 3857 I-upper_bound
prior 505 510 3858 3863 I-upper_bound
to 511 513 3864 3866 O
enrollment 514 524 3867 3877 O

Participants 0 12 3878 3890 O
who 13 16 3891 3894 O
have 17 21 3895 3899 O
received 22 30 3900 3908 O
any 31 34 3909 3912 O
other 35 40 3913 3918 O
investigational 41 56 3919 3934 B-treatment
agents 57 63 3935 3941 I-treatment
within 64 70 3942 3948 O
the 71 74 3949 3952 O
4 75 76 3953 3954 B-upper_bound
weeks 77 82 3955 3960 I-upper_bound
prior 83 88 3961 3966 I-upper_bound
to 89 91 3967 3969 O
enrollment 92 102 3970 3980 O
; 102 103 3980 3981 O
concurrent 104 114 3982 3992 B-treatment
radiation 115 124 3993 4002 I-treatment
therapy 125 132 4003 4010 I-treatment

Participants 0 12 4011 4023 O
with 13 17 4024 4028 O
clinical 18 26 4029 4037 O
or 27 29 4038 4040 O
radiographic 30 42 4041 4053 O
evidence 43 51 4054 4062 O
of 52 54 4063 4065 O
pancreatitis 55 67 4066 4078 B-chronic_disease

Platelets 0 9 4079 4088 B-clinical_variable
> 10 11 4089 4090 O
= 11 12 4090 4091 O
75,000 13 19 4092 4098 B-lower_bound
/ 19 20 4098 4099 I-lower_bound
mm^3 20 24 4099 4103 I-lower_bound
( 25 26 4104 4105 O
within 26 32 4105 4111 O
2 33 34 4112 4113 B-upper_bound
weeks 35 40 4114 4119 I-upper_bound
prior 41 46 4120 4125 I-upper_bound
to 47 49 4126 4128 O
enrollment 50 60 4129 4139 O
) 60 61 4139 4140 O

Platelets 0 9 4141 4150 B-clinical_variable
: 9 10 4150 4151 O
> 11 12 4152 4153 O
= 12 13 4153 4154 O
75,000 14 20 4155 4161 B-lower_bound
/ 20 21 4161 4162 I-lower_bound
mm^3 21 25 4162 4166 I-lower_bound
, 25 26 4166 4167 O
unless 27 33 4168 4174 O
decreased 34 43 4175 4184 O
due 44 47 4185 4188 O
to 48 50 4189 4191 O
bone 51 55 4192 4196 O
marrow 56 62 4197 4203 O
involvement 63 74 4204 4215 O
with 75 79 4216 4220 O
lymphoma 80 88 4221 4229 B-cancer
( 89 90 4230 4231 O
within 90 96 4231 4237 O
2 97 98 4238 4239 B-upper_bound
weeks 99 104 4240 4245 I-upper_bound
prior 105 110 4246 4251 I-upper_bound
to 111 113 4252 4254 O
enrollment 114 124 4255 4265 O
) 124 125 4265 4266 O
( 126 127 4267 4268 O
participants 127 139 4268 4280 O
may 140 143 4281 4284 O
receive 144 151 4285 4292 O
GCSF 152 156 4293 4297 B-clinical_variable
and 157 160 4298 4301 O
transfusions 161 173 4302 4314 O
to 174 176 4315 4317 O
meet 177 181 4318 4322 O
these 182 187 4323 4328 O
parameters 188 198 4329 4339 O
) 198 199 4339 4340 O

Prior 0 5 4341 4346 B-treatment
therapy 6 13 4347 4354 I-treatment
for 14 17 4355 4358 O
metastatic 18 28 4359 4369 B-cancer
disease 29 36 4370 4377 I-cancer

Repeat 0 6 4378 4384 O
imaging 7 14 4385 4392 O
demonstrates 15 27 4393 4405 O
no 28 30 4406 4408 O
new 31 34 4409 4412 O
sites 35 40 4413 4418 O
of 41 43 4419 4421 O
bone 44 48 4422 4426 B-cancer
metastases 49 59 4427 4437 I-cancer

Serum 0 5 4438 4443 B-clinical_variable
albumin 6 13 4444 4451 I-clinical_variable
> 14 15 4452 4453 O
= 15 16 4453 4454 O
2.8 17 20 4455 4458 B-lower_bound
g 21 22 4459 4460 I-lower_bound
/ 22 23 4460 4461 I-lower_bound
dL 23 25 4461 4463 I-lower_bound
( 26 27 4464 4465 O
within 27 33 4465 4471 O
2 34 35 4472 4473 B-upper_bound
weeks 36 41 4474 4479 I-upper_bound
prior 42 47 4480 4485 I-upper_bound
to 48 50 4486 4488 O
enrollment 51 61 4489 4499 O
) 61 62 4499 4500 O

Serum 0 5 4501 4506 B-clinical_variable
lipase 6 12 4507 4513 I-clinical_variable
and 13 16 4514 4517 I-clinical_variable
amylase 17 24 4518 4525 I-clinical_variable
< 25 26 4526 4527 O
1.5 27 30 4528 4531 B-upper_bound
x 31 32 4532 4533 I-upper_bound
ULN 33 36 4534 4537 I-upper_bound
( 37 38 4538 4539 O
within 38 44 4539 4545 O
2 45 46 4546 4547 B-upper_bound
weeks 47 52 4548 4553 I-upper_bound
prior 53 58 4554 4559 I-upper_bound
to 59 61 4560 4562 O
enrollment 62 72 4563 4573 O
) 72 73 4573 4574 O

Serum 0 5 4575 4580 B-clinical_variable
lipase 6 12 4581 4587 I-clinical_variable
and 13 16 4588 4591 I-clinical_variable
amylase 17 24 4592 4599 I-clinical_variable
< 25 26 4600 4601 O
1.5 27 30 4602 4605 B-upper_bound
x 31 32 4606 4607 I-upper_bound
ULN 33 36 4608 4611 I-upper_bound
( 37 38 4612 4613 O
within 38 44 4613 4619 O
2 45 46 4620 4621 B-upper_bound
weeks 47 52 4622 4627 I-upper_bound
prior 53 58 4628 4633 I-upper_bound
to 59 61 4634 4636 O
enrollment 62 72 4637 4647 O
) 72 73 4647 4648 O
( 74 75 4649 4650 O
participants 75 87 4650 4662 O
may 88 91 4663 4666 O
receive 92 99 4667 4674 O
GCSF 100 104 4675 4679 B-treatment
and 105 108 4680 4683 O
transfusions 109 121 4684 4696 O
to 122 124 4697 4699 O
meet 125 129 4700 4704 O
these 130 135 4705 4710 O
parameters 136 146 4711 4721 O
) 146 147 4721 4722 O

Solid 0 5 4723 4728 B-cancer
Tumor 6 11 4729 4734 I-cancer
Expansion 12 21 4735 4744 O
Cohort 22 28 4745 4751 O
: 28 29 4751 4752 O
CD4 30 33 4753 4756 B-clinical_variable
+ 33 34 4756 4757 I-clinical_variable
cell 35 39 4758 4762 I-clinical_variable
count 40 45 4763 4768 I-clinical_variable
greater 46 53 4769 4776 O
than 54 58 4777 4781 O
200 59 62 4782 4785 B-lower_bound
cells 63 68 4786 4791 I-lower_bound
/ 68 69 4791 4792 I-lower_bound
mm^3 69 73 4792 4796 I-lower_bound
obtained 74 82 4797 4805 O
within 83 89 4806 4812 O
2 90 91 4813 4814 B-upper_bound
weeks 92 97 4815 4820 I-upper_bound
prior 98 103 4821 4826 I-upper_bound
to 104 106 4827 4829 O
enrollment 107 117 4830 4840 O
at 118 120 4841 4843 O
any 121 124 4844 4847 O
U.S. 125 129 4848 4852 O
laboratory 130 140 4853 4863 O
that 141 145 4864 4868 O
has 146 149 4869 4872 O
a 150 151 4873 4874 O
clinical 152 160 4875 4883 O
laboratory 161 171 4884 4894 O
improvement 172 183 4895 4906 O
amendments 184 194 4907 4917 O
( 195 196 4918 4919 O
CLIA 196 200 4919 4923 O
) 200 201 4923 4924 O
certification 202 215 4925 4938 O
or 216 218 4939 4941 O
its 219 222 4942 4945 O
equivalent 223 233 4946 4956 O

The 0 3 4957 4960 O
effects 4 11 4961 4968 O
of 12 14 4969 4971 O
nivolumab 15 24 4972 4981 B-treatment
and 25 28 4982 4985 O
ipilimumab 29 39 4986 4996 B-treatment
on 40 42 4997 4999 O
the 43 46 5000 5003 O
developing 47 57 5004 5014 O
human 58 63 5015 5020 O
fetus 64 69 5021 5026 O
are 70 73 5027 5030 O
unknown 74 81 5031 5038 O
; 81 82 5038 5039 O
for 83 86 5040 5043 O
this 87 91 5044 5048 O
reason 92 98 5049 5055 O
and 99 102 5056 5059 O
because 103 110 5060 5067 O
other 111 116 5068 5073 O
therapeutic 117 128 5074 5085 B-treatment
agents 129 135 5086 5092 I-treatment
used 136 140 5093 5097 O
in 141 143 5098 5100 O
this 144 148 5101 5105 O
trial 149 154 5106 5111 O
are 155 158 5112 5115 O
known 159 164 5116 5121 O
to 165 167 5122 5124 O
be 168 170 5125 5127 O
teratogenic 171 182 5128 5139 B-treatment
, 182 183 5139 5140 O
women 184 189 5141 5146 B-gender
of 190 192 5147 5149 O
childbearing 193 205 5150 5162 O
potential 206 215 5163 5172 O
( 216 217 5173 5174 O
WOCBP 217 222 5174 5179 O
) 222 223 5179 5180 O
and 224 227 5181 5184 O
men 228 231 5185 5188 O
must 232 236 5189 5193 O
agree 237 242 5194 5199 B-contraception_consent
to 243 245 5200 5202 I-contraception_consent
use 246 249 5203 5206 I-contraception_consent
adequate 250 258 5207 5215 I-contraception_consent
contraception 259 272 5216 5229 I-contraception_consent
( 273 274 5230 5231 O
hormonal 274 282 5231 5239 B-contraception_consent
or 283 285 5240 5242 I-contraception_consent
barrier 286 293 5243 5250 I-contraception_consent
method 294 300 5251 5257 I-contraception_consent
of 301 303 5258 5260 I-contraception_consent
birth 304 309 5261 5266 I-contraception_consent
control 310 317 5267 5274 I-contraception_consent
; 317 318 5274 5275 O
abstinence 319 329 5276 5286 B-contraception_consent
) 329 330 5286 5287 O
prior 331 336 5288 5293 O
to 337 339 5294 5296 O
study 340 345 5297 5302 O
entry 346 351 5303 5308 O
and 352 355 5309 5312 O
for 356 359 5313 5316 O
the 360 363 5317 5320 O
duration 364 372 5321 5329 O
of 373 375 5330 5332 O
study 376 381 5333 5338 O
participation 382 395 5339 5352 O
; 395 396 5352 5353 O
WOCBP 397 402 5354 5359 O
should 403 409 5360 5366 O
use 410 413 5367 5370 O
an 414 416 5371 5373 O
adequate 417 425 5374 5382 O
method 426 432 5383 5389 O
to 433 435 5390 5392 O
avoid 436 441 5393 5398 O
pregnancy 442 451 5399 5408 B-pregnancy
for 452 455 5409 5412 O
6 456 457 5413 5414 B-upper_bound
months 458 464 5415 5421 I-upper_bound
after 465 470 5422 5427 I-upper_bound
the 471 474 5428 5431 O
last 475 479 5432 5436 O
dose 480 484 5437 5441 O
of 485 487 5442 5444 O
investigational 488 503 5445 5460 B-treatment
drug 504 508 5461 5465 I-treatment

The 0 3 5466 5469 O
lesion 4 10 5470 5476 O
being 11 16 5477 5482 O
considered 17 27 5483 5493 O
for 28 31 5494 5497 O
palliative 32 42 5498 5508 B-treatment
radiation 43 52 5509 5518 I-treatment
is 53 55 5519 5521 O
not 56 59 5522 5525 O
a 60 61 5526 5527 O
target 62 68 5528 5534 O
lesion 69 75 5535 5541 O

Total 0 5 5542 5547 B-clinical_variable
bilirubin 6 15 5548 5557 I-clinical_variable
= 16 17 5558 5559 O
< 17 18 5559 5560 O
1.5 19 22 5561 5564 B-upper_bound
x 23 24 5565 5566 I-upper_bound
institutional 25 38 5567 5580 I-upper_bound
upper 39 44 5581 5586 I-upper_bound
limit 45 50 5587 5592 I-upper_bound
of 51 53 5593 5595 I-upper_bound
normal 54 60 5596 5602 I-upper_bound
( 61 62 5603 5604 I-upper_bound
ULN 62 65 5604 5607 I-upper_bound
) 65 66 5607 5608 I-upper_bound
= 67 68 5609 5610 O
< 68 69 5610 5611 O
3 70 71 5612 5613 B-upper_bound
x 72 73 5614 5615 I-upper_bound
ULN 74 77 5616 5619 I-upper_bound
for 78 81 5620 5623 O
subjects 82 90 5624 5632 O
with 91 95 5633 5637 O
Gilbert 96 103 5638 5645 B-chronic_disease
's 103 105 5645 5647 I-chronic_disease
disease 106 113 5648 5655 I-chronic_disease
or 114 116 5656 5658 O
with 117 121 5659 5663 O
atazanavir- 122 133 5664 5675 B-treatment
or 134 136 5676 5678 O
indinavir 137 146 5679 5688 B-treatment
- 146 147 5688 5689 O
induced 147 154 5689 5696 O
unconjugated 155 167 5697 5709 O
hyperbilirubinemia 168 186 5710 5728 B-chronic_disease
without 187 194 5729 5736 O
aspartate 195 204 5737 5746 O
aminotransferase 205 221 5747 5763 O
( 222 223 5764 5765 O
AST 223 226 5765 5768 O
) 226 227 5768 5769 O
or 228 230 5770 5772 O
alanine 231 238 5773 5780 O
aminotransferase 239 255 5781 5797 O
( 256 257 5798 5799 O
ALT 257 260 5799 5802 O
) 260 261 5802 5803 O
elevation 262 271 5804 5813 O
and 272 275 5814 5817 O
must 276 280 5818 5822 O
have 281 285 5823 5827 O
a 286 287 5828 5829 O
total 288 293 5830 5835 B-clinical_variable
bilirubin 294 303 5836 5845 I-clinical_variable
less 304 308 5846 5850 O
than 309 313 5851 5855 O
3.0 314 317 5856 5859 B-upper_bound
mg 318 320 5860 5862 I-upper_bound
/ 320 321 5862 5863 I-upper_bound
dL 321 323 5863 5865 I-upper_bound
( 324 325 5866 5867 O
within 325 331 5867 5873 O
2 332 333 5874 5875 B-upper_bound
weeks 334 339 5876 5881 I-upper_bound
prior 340 345 5882 5887 I-upper_bound
to 346 348 5888 5890 O
enrollment 349 359 5891 5901 O
) 359 360 5901 5902 O

Total 0 5 5903 5908 B-clinical_variable
bilirubin 6 15 5909 5918 I-clinical_variable
: 15 16 5918 5919 O
= 17 18 5920 5921 O
< 18 19 5921 5922 O
1.5 19 22 5922 5925 B-upper_bound
x 23 24 5926 5927 I-upper_bound
institutional 25 38 5928 5941 I-upper_bound
upper 39 44 5942 5947 I-upper_bound
limit 45 50 5948 5953 I-upper_bound
of 51 53 5954 5956 I-upper_bound
normal 54 60 5957 5963 I-upper_bound
( 61 62 5964 5965 I-upper_bound
ULN 62 65 5965 5968 I-upper_bound
) 65 66 5968 5969 I-upper_bound
, 66 67 5969 5970 O
or 68 70 5971 5973 O
= 71 72 5974 5975 O
< 72 73 5975 5976 O
3 74 75 5977 5978 B-upper_bound
x 76 77 5979 5980 I-upper_bound
ULN 78 81 5981 5984 I-upper_bound
for 82 85 5985 5988 O
participants 86 98 5989 6001 O
with 99 103 6002 6006 O
Gilbert 104 111 6007 6014 B-chronic_disease
's 111 113 6014 6016 I-chronic_disease
disease 114 121 6017 6024 I-chronic_disease
or 122 124 6025 6027 O
with 125 129 6028 6032 O
atazanavir- 130 141 6033 6044 B-treatment
or 142 144 6045 6047 O
indinavir 145 154 6048 6057 B-treatment
- 154 155 6057 6058 O
induced 155 162 6058 6065 O
unconjugated 163 175 6066 6078 B-treatment
hyperbilirubinemia 176 194 6079 6097 I-treatment
without 195 202 6098 6105 O
AST 203 206 6106 6109 B-clinical_variable
or 207 209 6110 6112 O
ALT 210 213 6113 6116 B-clinical_variable
elevation 214 223 6117 6126 O
, 223 224 6126 6127 O
and 225 228 6128 6131 O
must 229 233 6132 6136 O
have 234 238 6137 6141 O
a 239 240 6142 6143 O
total 241 246 6144 6149 B-clinical_variable
bilirubin 247 256 6150 6159 I-clinical_variable
less 257 261 6160 6164 O
than 262 266 6165 6169 O
3.0 267 270 6170 6173 B-upper_bound
mg 271 273 6174 6176 I-upper_bound
/ 273 274 6176 6177 I-upper_bound
dL 274 276 6177 6179 I-upper_bound
) 276 277 6179 6180 O
( 278 279 6181 6182 O
within 279 285 6182 6188 O
2 286 287 6189 6190 B-upper_bound
weeks 288 293 6191 6196 I-upper_bound
prior 294 299 6197 6202 I-upper_bound
to 300 302 6203 6205 O
enrollment 303 313 6206 6216 O
) 313 314 6216 6217 O
( 315 316 6218 6219 O
participants 316 328 6219 6231 O
may 329 332 6232 6235 O
receive 333 340 6236 6243 O
GCSF 341 345 6244 6248 O
and 346 349 6249 6252 O
transfusions 350 362 6253 6265 O
to 363 365 6266 6268 O
meet 366 370 6269 6273 O
these 371 376 6274 6279 O
parameters 377 387 6280 6290 O
) 387 388 6290 6291 O

Uncontrolled 0 12 6292 6304 O
intercurrent 13 25 6305 6317 O
illness 26 33 6318 6325 O
including 34 43 6326 6335 O
, 43 44 6335 6336 O
but 45 48 6337 6340 O
not 49 52 6341 6344 O
limited 53 60 6345 6352 O
to 61 63 6353 6355 O
, 63 64 6355 6356 O
ongoing 65 72 6357 6364 O
or 73 75 6365 6367 O
active 76 82 6368 6374 B-chronic_disease
infection 83 92 6375 6384 I-chronic_disease
, 92 93 6384 6385 O
symptomatic 94 105 6386 6397 O
congestive 106 116 6398 6408 B-chronic_disease
heart 117 122 6409 6414 I-chronic_disease
failure 123 130 6415 6422 I-chronic_disease
, 130 131 6422 6423 O
unstable 132 140 6424 6432 B-chronic_disease
angina 141 147 6433 6439 I-chronic_disease
pectoris 148 156 6440 6448 O
, 156 157 6448 6449 O
cardiac 158 165 6450 6457 B-chronic_disease
arrhythmia 166 176 6458 6468 I-chronic_disease
, 176 177 6468 6469 O
or 178 180 6470 6472 O
psychiatric 181 192 6473 6484 O
illness 193 200 6485 6492 I-chronic_disease
/ 200 201 6492 6493 O
social 201 207 6493 6499 O
situations 208 218 6500 6510 O
that 219 223 6511 6515 O
would 224 229 6516 6521 O
limit 230 235 6522 6527 O
compliance 236 246 6528 6538 O
with 247 251 6539 6543 O
study 252 257 6544 6549 O
requirements 258 270 6550 6562 O

WOCBP 0 5 6563 6568 O
receiving 6 15 6569 6578 O
nivolumab 16 25 6579 6588 B-treatment
will 26 30 6589 6593 O
be 31 33 6594 6596 O
instructed 34 44 6597 6607 O
to 45 47 6608 6610 O
adhere 48 54 6611 6617 B-contraception_consent
to 55 57 6618 6620 I-contraception_consent
contraception 58 71 6621 6634 I-contraception_consent
for 72 75 6635 6638 O
a 76 77 6639 6640 O
period 78 84 6641 6647 O
of 85 87 6648 6650 O
6 88 89 6651 6652 B-upper_bound
months 90 96 6653 6659 I-upper_bound
after 97 102 6660 6665 I-upper_bound
the 103 106 6666 6669 O
last 107 111 6670 6674 O
dose 112 116 6675 6679 O
of 117 119 6680 6682 O
investigational 120 135 6683 6698 O
product 136 143 6699 6706 O

a 0 1 6707 6708 O
brief 2 7 6709 6714 O
course 8 14 6715 6721 O
of 15 17 6722 6724 O
corticosteroids 18 33 6725 6740 B-treatment
for 34 37 6741 6744 I-treatment
prophylaxis 38 49 6745 6756 I-treatment
( 50 51 6757 6758 O
e.g. 51 55 6758 6762 O
, 55 56 6762 6763 O
contrast 57 65 6764 6772 O
dye 66 69 6773 6776 B-allergy_name
allergy 70 77 6777 6784 I-allergy_name
) 77 78 6784 6785 O
or 79 81 6786 6788 O
for 82 85 6789 6792 O
treatment 86 95 6793 6802 B-treatment
of 96 98 6803 6805 O
non 99 102 6806 6809 O
- 102 103 6809 6810 O
autoimmune 103 113 6810 6820 O
conditions 114 124 6821 6831 O
( 125 126 6832 6833 O
e.g. 126 130 6833 6837 O
, 130 131 6837 6838 O
delayed 132 139 6839 6846 O
- 139 140 6846 6847 O
type 140 144 6847 6851 O
hypersensitivity 145 161 6852 6868 O
reaction 162 170 6869 6877 O
caused 171 177 6878 6884 O
by 178 180 6885 6887 O
contact 181 188 6888 6895 B-clinical_variable
allergen 189 197 6896 6904 I-clinical_variable
) 197 198 6904 6905 O

anabolic 0 8 6906 6914 B-treatment
steroids 9 17 6915 6923 I-treatment

delayed 0 7 6924 6931 O
- 7 8 6931 6932 O
type 8 12 6932 6936 O
hypersensitivity 13 29 6937 6953 O
reaction 30 38 6954 6962 O
caused 39 45 6963 6969 O
by 46 48 6970 6972 O
contact 49 56 6973 6980 B-allergy_name
allergen 57 65 6981 6989 I-allergy_name

for 0 3 6990 6993 O
participants 4 16 6994 7006 O
with 17 21 7007 7011 O
Kaposi 22 28 7012 7018 B-cancer
sarcoma 29 36 7019 7026 I-cancer
, 36 37 7026 7027 O
the 38 41 7028 7031 O
following 42 51 7032 7041 O
apply 52 57 7042 7047 O
: 57 58 7047 7048 O
at 59 61 7049 7051 O
least 62 67 7052 7057 O
five 68 72 7058 7062 B-lower_bound
measurable 73 83 7063 7073 O
cutaneous 84 93 7074 7083 O
KS 94 96 7084 7086 O
lesions 97 104 7087 7094 O
or 105 107 7095 7097 O
any 108 111 7098 7101 O
number 112 118 7102 7108 O
of 119 121 7109 7111 O
lesions 122 129 7112 7119 O
with 130 134 7120 7124 O
systemic 135 143 7125 7133 O
unresectable 144 156 7134 7146 O
disease 157 164 7147 7154 O
with 165 169 7155 7159 O
no 170 172 7160 7162 O
previous 173 181 7163 7171 B-treatment
local 182 187 7172 7177 I-treatment
radiation 188 197 7178 7187 I-treatment
, 197 198 7187 7188 O
surgical 199 207 7189 7197 B-treatment
, 207 208 7197 7198 O
or 209 211 7199 7201 O
intralesional 212 225 7202 7215 B-treatment
cytotoxic 226 235 7216 7225 I-treatment
therapy 236 243 7226 7233 I-treatment
that 244 248 7234 7238 O
would 249 254 7239 7244 O
prevent 255 262 7245 7252 O
response 263 271 7253 7261 O
assessment 272 282 7262 7272 O

men 0 3 7273 7276 B-gender
receiving 4 13 7277 7286 O
nivolumab 14 23 7287 7296 B-treatment
and 24 27 7297 7300 O
who 28 31 7301 7304 O
are 32 35 7305 7308 O
sexually 36 44 7309 7317 O
active 45 51 7318 7324 O
with 52 56 7325 7329 O
WOCBP 57 62 7330 7335 O
will 63 67 7336 7340 O
be 68 70 7341 7343 O
instructed 71 81 7344 7354 O
to 82 84 7355 7357 O
adhere 85 91 7358 7364 B-contraception_consent
to 92 94 7365 7367 I-contraception_consent
contraception 95 108 7368 7381 I-contraception_consent
for 109 112 7382 7385 O
a 113 114 7386 7387 O
period 115 121 7388 7394 O
of 122 124 7395 7397 O
31 125 127 7398 7400 B-upper_bound
weeks 128 133 7401 7406 I-upper_bound
after 134 139 7407 7412 I-upper_bound
the 140 143 7413 7416 O
last 144 148 7417 7421 O
dose 149 153 7422 7426 O
of 154 156 7427 7429 O
investigational 157 172 7430 7445 B-treatment
product 173 180 7446 7453 I-treatment

men 0 3 7454 7457 B-gender
who 4 7 7458 7461 O
are 8 11 7462 7465 O
sexually 12 20 7466 7474 O
active 21 27 7475 7481 O
with 28 32 7482 7486 O
WOCBP 33 38 7487 7492 O
must 39 43 7493 7497 O
use 44 47 7498 7501 B-contraception_consent
any 48 51 7502 7505 I-contraception_consent
contraceptive 52 65 7506 7519 I-contraception_consent
method 66 72 7520 7526 I-contraception_consent
with 73 77 7527 7531 O
a 78 79 7532 7533 O
failure 80 87 7534 7541 B-clinical_variable
rate 88 92 7542 7546 I-clinical_variable
of 93 95 7547 7549 O
less 96 100 7550 7554 O
than 101 105 7555 7559 O
1 106 107 7560 7561 B-upper_bound
% 107 108 7561 7562 I-upper_bound
per 109 112 7563 7566 I-upper_bound
year 113 117 7567 7571 I-upper_bound

palliative 0 10 7572 7582 B-treatment
( 11 12 7583 7584 I-treatment
limited 12 19 7584 7591 I-treatment
- 19 20 7591 7592 I-treatment
field 20 25 7592 7597 I-treatment
) 25 26 7597 7598 I-treatment
radiation 27 36 7599 7608 I-treatment
therapy 37 44 7609 7616 I-treatment

participants 0 12 7617 7629 O
will 13 17 7630 7634 O
be 18 20 7635 7637 O
eligible 21 29 7638 7646 O
regardless 30 40 7647 7657 O
of 41 43 7658 7660 O
antiretroviral 44 58 7661 7675 B-treatment
medication 59 69 7676 7686 I-treatment
( 70 71 7687 7688 O
including 71 80 7688 7697 O
no 81 83 7698 7700 O
antiretroviral 84 98 7701 7715 O
medication 99 109 7716 7726 O
) 109 110 7726 7727 O
provided 111 119 7728 7736 O
there 120 125 7737 7742 O
is 126 128 7743 7745 O
no 129 131 7746 7748 O
intention 132 141 7749 7758 O
to 142 144 7759 7761 O
initiate 145 153 7762 7770 O
therapy 154 161 7771 7778 B-treatment
or 162 164 7779 7781 O
the 165 168 7782 7785 O
regimen 169 176 7786 7793 B-treatment
has 177 180 7794 7797 O
been 181 185 7798 7802 O
stable 186 192 7803 7809 O
for 193 196 7810 7813 O
at 197 199 7814 7816 O
least 200 205 7817 7822 O
4 206 207 7823 7824 B-lower_bound
weeks 208 213 7825 7830 I-lower_bound
with 214 218 7831 7835 O
no 219 221 7836 7838 O
intention 222 231 7839 7848 O
to 232 234 7849 7851 O
change 235 241 7852 7858 O
the 242 245 7859 7862 O
regimen 246 253 7863 7870 O
within 254 260 7871 7877 O
12 261 263 7878 7880 B-upper_bound
weeks 264 269 7881 7886 I-upper_bound
following 270 279 7887 7896 O
enrollment 280 290 7897 7907 O

participants 0 12 7908 7920 O
with 13 17 7921 7925 O
uncontrolled 18 30 7926 7938 O
Kaposi 31 37 7939 7945 B-cancer
sarcoma 38 45 7946 7953 I-cancer
are 46 49 7954 7957 O
permitted 50 59 7958 7967 O
( 60 61 7968 7969 O
KS 61 63 7969 7971 B-cancer
must 64 68 7972 7976 O
be 69 71 7977 7979 O
increasing 72 82 7980 7990 O
despite 83 90 7991 7998 O
HAART 91 96 7999 8004 B-treatment
and 97 100 8005 8008 O
HIV 101 104 8009 8012 B-treatment
suppression 105 116 8013 8024 I-treatment
for 117 120 8025 8028 O
greater 121 128 8029 8036 O
than 129 133 8037 8041 O
or 134 136 8042 8044 O
equal 137 142 8045 8050 O
to 143 145 8051 8053 O
2 146 147 8054 8055 B-lower_bound
months 148 154 8056 8062 I-lower_bound
, 154 155 8062 8063 O
or 156 158 8064 8066 O
stable 159 165 8067 8073 O
KS 166 168 8074 8076 O
despite 169 176 8077 8084 O
HAART 177 182 8085 8090 O
for 183 186 8091 8094 O
greater 187 194 8095 8102 O
than 195 199 8103 8107 O
or 200 202 8108 8110 O
equal 203 208 8111 8116 O
to 209 211 8117 8119 O
3 212 213 8120 8121 B-lower_bound
months 214 220 8122 8128 I-lower_bound

radiotherapy 0 12 8129 8141 B-treatment
must 13 17 8142 8146 O
be 18 20 8147 8149 O
completed 21 30 8150 8159 O
at 31 33 8160 8162 O
least 34 39 8163 8168 O
4 40 41 8169 8170 B-lower_bound
weeks 42 47 8171 8176 I-lower_bound
prior 48 53 8177 8182 I-lower_bound
to 54 56 8183 8185 O
registration 57 69 8186 8198 O

scans 0 5 8199 8204 O
must 6 10 8205 8209 O
have 11 15 8210 8214 O
been 16 20 8215 8219 O
performed 21 30 8220 8229 O
within 31 37 8230 8236 O
4 38 39 8237 8238 B-upper_bound
weeks 40 45 8239 8244 I-upper_bound
prior 46 51 8245 8250 I-upper_bound
to 52 54 8251 8253 O
registration 55 67 8254 8266 O

the 0 3 8267 8270 O
referring 4 13 8271 8280 O
physician 14 23 8281 8290 O
's 23 25 8290 8292 O
written 26 33 8293 8300 O
record 34 40 8301 8307 O
that 41 45 8308 8312 O
HIV 46 49 8313 8316 B-chronic_disease
infection 50 59 8317 8326 I-chronic_disease
was 60 63 8327 8330 O
documented 64 74 8331 8341 O
, 74 75 8341 8342 O
with 76 80 8343 8347 O
supporting 81 91 8348 8358 O
information 92 103 8359 8370 O
on 104 106 8371 8373 O
the 107 110 8374 8377 O
participant 111 122 8378 8389 O
's 122 124 8389 8391 O
relevant 125 133 8392 8400 O
medical 134 141 8401 8408 O
history 142 149 8409 8416 O
and/or 150 156 8417 8423 O
current 157 164 8424 8431 O
management 165 175 8432 8442 O
of 176 178 8443 8445 O
HIV 179 182 8446 8449 O
infection 183 192 8450 8459 O

the 0 3 8460 8463 O
result 4 10 8464 8470 O
must 11 15 8471 8475 O
be 16 18 8476 8478 O
obtained 19 27 8479 8487 O
within 28 34 8488 8494 O
12 35 37 8495 8497 O
weeks 38 43 8498 8503 O
prior 44 49 8504 8509 O
to 50 52 8510 8512 O
enrollment 53 63 8513 8523 O
; 63 64 8523 8524 O
PPD 65 68 8525 8528 B-chronic_disease
positive 69 77 8529 8537 O
( 78 79 8538 8539 O
or 79 81 8539 8541 O
Quantiferon 82 93 8542 8553 O
assay 94 99 8554 8559 O
positive 100 108 8560 8568 O
) 108 109 8568 8569 O
participants 110 122 8570 8582 O
are 123 126 8583 8586 O
permitted 127 136 8587 8596 O
if 137 139 8597 8599 O
prophylaxis 140 151 8600 8611 B-treatment
has 152 155 8612 8615 O
been 156 160 8616 8620 O
completed 161 170 8621 8630 O
prior 171 176 8631 8636 O
to 177 179 8637 8639 O
enrollment 180 190 8640 8650 O

use 0 3 8651 8654 O
of 4 6 8655 8657 O
anabolic 7 15 8658 8666 B-treatment
steroids 16 24 8667 8675 I-treatment

women 0 5 8676 8681 B-gender
must 6 10 8682 8686 O
not 11 14 8687 8690 O
be 15 17 8691 8693 O
breastfeeding 18 31 8694 8707 O

women 0 5 8708 8713 B-gender
of 6 8 8714 8716 O
childbearing 9 21 8717 8729 O
potential 22 31 8730 8739 O
must 32 36 8740 8744 O
have 37 41 8745 8749 O
a 42 43 8750 8751 O
negative 44 52 8752 8760 B-pregnancy
serum 53 58 8761 8766 I-pregnancy
or 59 61 8767 8769 I-pregnancy
urine 62 67 8770 8775 I-pregnancy
pregnancy 68 77 8776 8785 I-pregnancy
test 78 82 8786 8790 O
( 83 84 8791 8792 O
minimum 84 91 8792 8799 O
sensitivity 92 103 8800 8811 O
25 104 106 8812 8814 B-lower_bound
IU 107 109 8815 8817 I-lower_bound
/ 109 110 8817 8818 I-lower_bound
L 110 111 8818 8819 I-lower_bound
or 112 114 8820 8822 O
equivalent 115 125 8823 8833 O
units 126 131 8834 8839 O
of 132 134 8840 8842 O
human 135 140 8843 8848 O
chorionic 141 150 8849 8858 O
gonadotropic 151 163 8859 8871 O
[ 164 165 8872 8873 O
HCG 165 168 8873 8876 B-clinical_variable
] 168 169 8876 8877 O
) 169 170 8877 8878 O
within 171 177 8879 8885 O
72 178 180 8886 8888 B-upper_bound
hours 181 186 8889 8894 I-upper_bound
prior 187 192 8895 8900 I-upper_bound
enrollment 193 203 8901 8911 O
and 204 207 8912 8915 O
the 208 211 8916 8919 O
start 212 217 8920 8925 O
of 218 220 8926 8928 O
nivolumab 221 230 8929 8938 B-treatment

